Specialty pharmacy costs are surging, and the traditional separation between pharmacy and medical benefits isn't helping. Prime Therapeutics, a pharmacy benefit manager jointly owned by 19 Blue Cross Blue Shield plans, is making a bold push to break down those silos — arguing that patients with complex conditions don't experience their care in two separate buckets, so their coverage shouldn't either.

At its annual Specialty Summit, Prime's leadership outlined how the company is repositioning itself from a drug dispenser to a full care coordination partner. A key piece of that strategy is its IntegratedRx program, which lets patients fill certain specialty prescriptions either at an in-house pharmacy or directly at their doctor's office — keeping providers and pharmacists in direct communication. Prime says its economic model, which isn't tied to drug fulfillment, gives it the flexibility to prioritize what's clinically and financially optimal for patients.

By the Numbers:

• 43% of employers and benefit leaders cite managing specialty pharmacy spend as a top goal
• 76% of novel FDA-approved drugs in 2025 were specialty products
• ~50% of specialty pharmacy spend sits within the medical benefit
• 3% of patients drive ~60% of pharmacy benefit spending; 10–13% drive over 90% of total drug costs when the medical benefit is included
• IntegratedRx has achieved a 9% reduction in total cost of care, with 95% patient satisfaction

Why it matters: As specialty drug costs continue to climb, integrated benefit management could become a critical lever for payers and employers. Prime's model offers a glimpse at how the industry might evolve to deliver more personalized, cost-effective care for the highest-need patients.